Related Experiment Videos
Hypokalemia during the treatment of arterial hypertension with diuretics
Insights
Hydrochlorothiazide treatment for hypertension effectively lowers blood pressure. Routine potassium supplements are unnecessary, as serum potassium levels normalize over time, avoiding dangerous hyperkalemia.
Area of Science:
- Cardiology
- Pharmacology
- Nephrology
Background:
- Arterial hypertension is a significant cardiovascular risk factor.
- Diuretics, such as thiazides, are commonly prescribed for hypertension.
- Concerns exist regarding diuretic-induced hypokalemia and the routine use of potassium supplements.
Purpose of the Study:
- To evaluate the effect of hydrochlorothiazide on blood pressure and serum potassium levels in hypertensive patients.
- To assess the necessity of routine potassium supplementation during thiazide therapy.
Main Methods:
- A study involving 50 patients with uncomplicated arterial hypertension.
- Administration of hydrochlorothiazide (50-100 mg daily/every other day), with or without reserpine.
- Monitoring of blood pressure and serum potassium concentrations over a mean duration of 19 months.
Main Results:
- Mean blood pressure decreased significantly from 182/113 to 144/92 mm Hg.
- Serum potassium initially decreased but stabilized above 3.5 mmol/l and spontaneously rose to 4.1 mmol/l by 19 months.
- All patients remained asymptomatic, with no significant hypokalemia observed.
Conclusions:
- Routine potassium supplementation or use of potassium-sparing diuretics may not be necessary with hydrochlorothiazide therapy for hypertension.
- Spontaneous normalization of serum potassium levels can occur during long-term thiazide treatment.
- Careful monitoring of serum potassium is crucial, especially when potassium supplements or sparing agents are used concurrently due to hyperkalemia risk.
Abstract:
In a study of 50 patients with uncomplicated arterial hypertension the administration of hydrochlorothiazide, 50 to 100 mg daily or every other day, with or without reserpine, 0.25 mg daily, resulted in a fall in the mean blood pressure from 182/113 to 144/92 mm Hg. The mean duration of therapy was 19 months. The mean serum potassium concentration was 4.3 mmol/l before the onset of therapy. It fell during the first 6 weeks of treatment, but seldom below 3.5 mmol/l, then rose gradually and spontaneously to 4.1 mmol/l after 19 months of therapy. All the patients remained asymptomatic. These findings bring into question the routine use of potassium supplements or a potassium-sparing diuretic, such as spironolactone or triamterene, during the treatment of hypertension with diuretics such as the thiazides. The use of potassium supplements or a potassium-sparing agent may induce hyperkalemia in spite of the simultaneous administration of a diuretic that acts more proximally. Since hyperkalemia is potentially lethal, the serum potassium concentration should be carefully monitored in any patient receiving potassium supplements or a potassium-sparing agent.